Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

You may be eligible if

• Subjects must:
• have a dysfunctional Central Venous Access Device (CVAD) defined as unable to withdraw 3 mL blood
• have had the device in place for \> 48 hours
• be clinically stable
• be 18 or older
• give informed consent